Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Non Operating Investment Income: 2020-2023

Historic Non Operating Investment Income for Avidity Biosciences (RNA) over the last 2 years, with Jun 2023 value amounting to -$1.1 million.

  • Avidity Biosciences' Non Operating Investment Income fell 18.44% to -$1.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $320,000, marking a year-over-year increase of 110.72%. This contributed to the annual value of -$2.5 million for FY2022, which is 1279.67% down from last year.
  • As of Q2 2023, Avidity Biosciences' Non Operating Investment Income stood at -$1.1 million, which was down 197.26% from $1.2 million recorded in Q1 2023.
  • In the past 5 years, Avidity Biosciences' Non Operating Investment Income registered a high of $1.2 million during Q1 2023, and its lowest value of -$1.8 million during Q1 2022.
  • Its 3-year average for Non Operating Investment Income is -$266,100, with a median of -$93,500 in 2021.
  • Within the past 5 years, the most significant YoY rise in Avidity Biosciences' Non Operating Investment Income was 511.29% (2022), while the steepest drop was 92,050.00% (2022).
  • Over the past 4 years, Avidity Biosciences' Non Operating Investment Income (Quarterly) stood at -$5,000 in 2020, then tumbled by 3,620.00% to -$186,000 in 2021, then surged by 511.29% to $765,000 in 2022, then declined by 18.44% to -$1.1 million in 2023.
  • Its Non Operating Investment Income was -$1.1 million in Q2 2023, compared to $1.2 million in Q1 2023 and $765,000 in Q4 2022.